Trial Profile

A double-blind, parallel group, randomized, placebo-controlled study of Nicotinamide Riboside for progressing glaucoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nicotinamide riboside (Primary)
Indications Glaucoma
Focus Adverse reactions
Sponsors ChromaDex; Niagen Bioscience

Most Recent Events

13 Mar 2025 According to ChromaDex Corporation media release, ChromaDex Corp has changed its name to Niagen Bioscience.
25 Jul 2023 New trial record
18 Jul 2023 According to a ChromaDex media release, data from this study were published at the in the peer-reviewed ARVO journal, Investigative Ophthalmology & Visual Science, by Dr. Christopher Leung.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com